Size | Price | Stock | Qty |
---|---|---|---|
500mg |
|
||
1g |
|
||
2g |
|
||
5g |
|
||
10g |
|
||
Other Sizes |
|
Purity: ≥98%
Polymyxin B (also known as Aerosporin, PMB, Poly-RX) is an antibiotic and a cationic surfactant primarily used for resistant gram-negative infections. Polymyxin B sulfate is a mixture of polymyxins B1 and B2, obtained from Bacillus polymyxa strains. They are basic polypeptides of about eight amino acids and have cationic detergent action on cell membranes. Polymyxin B is used for infections with gram-negative organisms, but may be neurotoxic and nephrotoxic.
ln Vitro |
MICs of 0.5 mg/l for E. Coli strain IH3080 are demonstrated by Polymyxin B Sulfate's antibacterial properties.
|
---|---|
ln Vivo |
A mouse model of lung or thigh infection demonstrates antibacterial activity when treated with Polymyxin B Sulfate (0.5-120 mg/kg; s.c.).
The mouse bactericidal effect of Polymyxin B Sulfate (2 mg/kg, s.c.) against E. coli strain IH3080 is strong. |
Animal Protocol |
Animal Model: Eight-week-old, 24-30 g, female Swiss mice[2]
Dosage: For the model of thigh infection, 0.5-120 mg/kg; for the lung infection mode, 5-120 mg/kg Administration: S.c. Result: demonstrated antibacterial activity against three strains of K. pneumoniae. |
References |
Molecular Formula |
C56H98N16O13.H2SO4
|
|
---|---|---|
Molecular Weight |
1301.56
|
|
Elemental Analysis |
C, 51.68; H, 7.74; N, 17.22; O, 20.90; S, 2.46
|
|
CAS # |
1405-20-5
|
|
Related CAS # |
|
|
Appearance |
Solid powder
|
|
SMILES |
OS(=O)(=O)O.CCC(CCCCC(NC(C(NC(C(NC(C(NC1C(=O)NC(CCN)C(=O)NC(CC2C=CC=CC=2)C(=O)NC(CC(C)C)C(=O)NC(CCN)C(=O)NC(CCN)C(=O)NC(C(O)C)C(=O)NCC1)=O)CCN)=O)C(O)C)=O)CCN)=O)C
|
|
InChi Key |
HFMDLUQUEXNBOP-UHFFFAOYSA-N
|
|
InChi Code |
InChI=1S/C56H98N16O13.H2O4S/c1-7-32(4)13-11-12-16-44(75)63-36(17-23-57)51(80)72-46(34(6)74)56(85)68-39(20-26-60)48(77)67-41-22-28-62-55(84)45(33(5)73)71-52(81)40(21-27-61)65-47(76)37(18-24-58)66-53(82)42(29-31(2)3)69-54(83)43(30-35-14-9-8-10-15-35)70-49(78)38(19-25-59)64-50(41)79;1-5(2,3)4/h8-10,14-15,31-34,36-43,45-46,73-74H,7,11-13,16-30,57-61H2,1-6H3,(H,62,84)(H,63,75)(H,64,79)(H,65,76)(H,66,82)(H,67,77)(H,68,85)(H,69,83)(H,70,78)(H,71,81)(H,72,80);(H2,1,2,3,4)
|
|
Chemical Name |
N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methyloctanamide;sulfuric acid
|
|
Synonyms |
KS-1428; KS 1428; KS1428; Polymyxin B Sulfate.
|
|
HS Tariff Code |
2934.99.9001
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : ~33.33 mg/mL
H2O : ~16.67 mg/mL |
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 0.71 mg/mL (Infinity mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 7.1 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 0.71 mg/mL (Infinity mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 7.1 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 0.71 mg/mL (Infinity mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 10% DMSO+40% PEG300+5% Tween-80+45% Saline: ≥ 0.71 mg/mL (Infinity mM) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 0.7683 mL | 3.8415 mL | 7.6831 mL | |
5 mM | 0.1537 mL | 0.7683 mL | 1.5366 mL | |
10 mM | 0.0768 mL | 0.3842 mL | 0.7683 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Total plasma polymyxin B concentration versus time after administration of single subcutaneous doses of 2, 4, 8, 16 or 32 mg/kg polymyxin B in neutropenic infected mice. [2]. J Antimicrob Chemother. 2018 Feb 1;73(2):462-468. td> |
Diagram of the final population pharmacokinetic model. SC, subcutaneous. [2]. J Antimicrob Chemother. 2018 Feb 1;73(2):462-468. td> |
Visual predictive checks of the model fits to the plasma polymyxin B concentration versus time data, stratified by dose. [2]. J Antimicrob Chemother. 2018 Feb 1;73(2):462-468. td> |
Relationships for K. pneumoniae FADDI-KP032 between log10 cfu per thigh at 24 h and fAUC/MIC (a) and log10 cfu per lung at 24 h and fAUC/MIC (b). [2]. J Antimicrob Chemother. 2018 Feb 1;73(2):462-468. td> |